Iliparcil is an antithrombotic compound with oral activity.

The effect of Iliparcil, a new orally active beta-D-xyloside venous antithrombotic, was studied on the thrombosis following thrombolytic therapy in rats, using a modified Umetsu model. The compound was administered by oral route prior to thrombolytic therapy, which consisted of administering a combination of heparin and urokinase (H/U) at 37.5 and 70,000 IU/kg, respectively. Time to occlusion increased from 3.9 min with saline to 10.5 min following H/U injection. When Iliparcil (30 mg/kg, oral route) was administered 4 h before H/U injection, the time to occlusion was increased by 250% compared with H/U alone (p < 0.001). Similarly, dermatan sulfate (DS), administered intravenously (3 mg/kg) 5 min before thrombus induction, also increased the time to occlusion (300% compared with H/U alone; p < 0.001). It was also shown that times to occlusion following Iliparcil or DS treatments were still increased even when heparin dosage was decreased.[1]